HEFFTER BLOG

[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="full_width" angled_section="no" text_align="left" background_image_as_pattern="without_pattern"][vc_column][vc_column_text]

Dear Friends and Supporters,

The Heffter Research Institute is celebrating 25 years of progress this year, having been incorporated in 1993!  We are hearing from more and more scientists who are becoming interested in the therapeutic potential of psilocybin-assisted therapy, and 2018 has been an exciting year of expansion, with new projects starting and in development.

Yale University, Department of Psychiatry

 

DOWNLOAD PDF

Purpose:

This study will investigate neurobiological and psychological effects of psilocybin-assisted therapy in people with major depressive disorder. The primary hypothesis is that psilocybin administered in a therapeutic context will result in neuroplastic changes that parallel improvement in symptoms of depression.

2018 is bringing new opportunities for Heffter's research mission.  As the FDA Phase 3 work on psilocybin-assisted therapy for depression proceeds at the Usona Institute, Heffter is moving forward with its agenda to support research to test psilocybin's healing potential for other conditions, such as addictions, eating disorders, and Alzheimer's disease.

The work ahead is only possible because of the decades of work by scientists and supporters alike who are dedicated to psychedelic research and have been working together to bring a dream into reality.

We note that along with MAPS, the Beckley Foundation, and others, the Heffter Institute endorses the statement on open science initiated by Bob Jesse.  You can read the statement here: Statement on Open Science and Open Praxis. The statement affirms a continuing commitment to our nonprofit status.

Recently there has been increased interest in microdosing LSD, that is, using doses of LSD that are not psychoactive (typically 10 micrograms).  A standard recommendation is microdosing every three days. The basic idea derives from earlier studies of psychoactive doses of LSD or other psychedelics...

With Phase 2 studies on cancer-related depression and anxiety now complete, Heffter is excited to investigate other conditions that might be successfully treated with psilocybin.

Drawing on the scientific expertise and longstanding partnership of the world’s leading investigators of psychedelics, Heffter mentors the next generation of psilocybin researchers and therapists, vets new approaches, supports proof-of-concept studies, and gathers the evidence base for therapeutic treatments that, pending FDA approval, will be available to patients in need.

Heffter Research Institute is proud to have supported new psilocybin studies published December 1 in The Journal of Psychopharmacology reporting the effectiveness of using psilocybin to reduce depression, anxiety and existential distress in cancer patients. Below is a round-up of articles discussing the recent findings...